For more information on Age-Related Macular Degeneration go to the NHS website. If you've had a diagnosis, in addition to ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Astellas Pharma has submitted an NDA to Japan's Ministry of Health, Labour and Welfare seeking conditional approval of ACP.

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Collaboration between TLI and AMDF underscores a shared commitment to making a meaningful difference in the lives of those ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...